NASDAQ:VCYTVeracyte Stock Price, Forecast & News

Veracyte's stock was trading at $23.55 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VCYT shares have increased by 43.4% and is now trading at $33.78.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Veracyte.

Veracyte is scheduled to release its next quarterly earnings announcement on Tuesday, October 27th 2020.
View our earnings forecast for Veracyte.

Veracyte Inc (NASDAQ:VCYT) posted its earnings results on Thursday, July, 30th. The biotechnology company reported ($0.22) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.22). The biotechnology company had revenue of $20.70 million for the quarter, compared to analysts' expectations of $17.56 million. Veracyte had a negative net margin of 27.49% and a negative return on equity of 13.35%.
View Veracyte's earnings history.

3 brokers have issued twelve-month target prices for Veracyte's stock. Their forecasts range from $37.00 to $40.00. On average, they anticipate Veracyte's stock price to reach $38.00 in the next year. This suggests a possible upside of 12.5% from the stock's current price.
View analysts' price targets for Veracyte.

Headlines about VCYT stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Veracyte earned a news sentiment score of -1.5 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about Veracyte.

Veracyte saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 3,610,000 shares, an increase of 42.7% from the December 31st total of 2,530,000 shares. Based on an average daily trading volume, of 498,600 shares, the short-interest ratio is currently 7.2 days. Currently, 7.7% of the company's stock are short sold.
View Veracyte's Short Interest.

Some companies that are related to Veracyte include ELEKTA AB/ADR (EKTAY), Natera (NTRA), InVitae (NVTA), CareDx (CDNA), RadNet (RDNT), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Personalis (PSNL), ALX Oncology (RNLX), Progenity (PROG), Centogene (CNTG), DermTech (DMTK), Biocept (BIOC), Enzo Biochem (ENZ) and Anpac Bio-Medical Science (ANPC).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), AbbVie (ABBV), CA (CA), InVitae (NVTA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Editas Medicine (EDIT), Exelixis (EXEL) and Gilead Sciences (GILD).

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Veracyte's stock is owned by a variety of institutional and retail investors. Top institutional investors include William Blair Investment Management LLC (8.50%), Sumitomo Mitsui Trust Holdings Inc. (6.28%), GW&K Investment Management LLC (2.35%), New York State Common Retirement Fund (1.67%), Bank of New York Mellon Corp (1.36%) and Granite Investment Partners LLC (1.36%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy, Jesse I Treu, John Walter Hanna Jr, John Walter Hanna, Jr, Keith Kennedy and Robert S Epstein.
View institutional ownership trends for Veracyte.

VCYT stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., William Blair Investment Management LLC, Sumitomo Mitsui Trust Holdings Inc., UBS Group AG, Skandinaviska Enskilda Banken AB publ , GW&K Investment Management LLC, Essex Investment Management Co. LLC, and Bank of Montreal Can. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, John Walter Hanna Jr, John Walter Hanna, Jr, Keith Kennedy, and Robert S Epstein.
View insider buying and selling activity for Veracyte.

VCYT stock was bought by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Candriam Luxembourg S.C.A., Bank of New York Mellon Corp, Rafferty Asset Management LLC, Swiss National Bank, Barclays PLC, Exchange Traded Concepts LLC, and Spearhead Capital Advisors LLC.
View insider buying and selling activity for Veracyte.

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VCYT stock can currently be purchased for approximately $33.78.

Veracyte has a market capitalization of $1.71 billion and generates $120.37 million in revenue each year. The biotechnology company earns $-12,600,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Veracyte employs 270 workers across the globe.

The official website for Veracyte is www.veracyte.com.

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]